查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363166

美国分子诊断市场规模、份额和趋势分析报告：按疾病、最终用途和细分市场预测，2023-2030 年

U.S. Molecular Diagnostics Market Size, Share & Trends Analysis Report By Disease (Healthcare-associated Infections, Respiratory), By End-use (Hospital Core Laboratory, Decentralized Test Sites), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

美国分子诊断市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计2030年美国分子诊断市场规模将达84.6亿美元，2023年至2030年年复合成长率为4.82%。

市场成长是由于人们越来越意识到实施分子诊断测试的好处，例如早期和快速检测病毒和细菌。此外，由于医疗保健部门的成熟和有利的报销政策而带来的便利性预计将在预测期内推动市场成长。

此外，业内主要企业正在投资于分子诊断技术的技术进步，以开发减少人力并提供即时结果的解决方案。例如，QIAGEN 推出了用于诊断实验室应用的 EZ2 Connect MDx 平台。该平台具有先进的自动化功能，可在 30 分钟的周转时间内从 24 个检体中精製RNA 和 DNA。

快速检测分析新兴市场的开拓预计将支持市场成长。这些测试透过加快决策速度和减少分散式检查的周转时间，彻底改变了市场。许多公司正在开发检测方法和分子诊断系统。用于诊断淋病奈瑟菌、沙眼衣原体的 Qiagen 的 Digene HC2 GC-ID DNA 测试和用于诊断生殖支原体并鉴定霉浆菌内酯抗药性的Danaher (Cepheid) ResistancePlus MG FleXible 都是此类产品的范例。

雅培、西门子医疗、QIAGEN、罗氏、丹纳赫、赛默飞世尔科技、Hologic Inc 和 BD 等市场主要企业正在提高基本客群。例如，2023 年 1 月，赛默飞世尔科技和阿斯特捷利康合作开发 Tagrisso 的血液和固态组织伴随诊断测试。

COVID-19 大流行对该行业产生了积极影响，刺激了能够检测冠状病毒的快速新型诊断试剂盒的开发。这导致感染疾病领域主要市场参与企业的收益增加。例如，赛默飞世尔科技 (Thermo Fisher Scientific) 报告称，由于诊断试剂盒需求增加，2021 年 4 月收益增加了 150%。然而，该地区的疫苗普及正在取得进展，预计在预测期内对 COVID-19 检测的需求将下降。

美国分子诊断市场报告亮点

  • 按疾病划分，2022年呼吸系统疾病领域占据市场主导地位。这种增长是由于呼吸道感染疾病的患病不断增加以及人们对感染疾病诊断和治疗的诊断测试的可用性的认识不断提高。
  • 按最终用途，医院核心实验室在 2022 年占据最大份额，由于 MRSA、金黄色葡萄球菌 (SA) 和肠病毒感染疾病的患病不断增加，在预测期内以最快的年复合成长率增长。
  • 主要行业参与者采取了各种策略，例如新产品发布、联盟、收购和业务扩张，以提高产品渗透率并获得更大的消费群。

目录

第1章调查方法和范围

第2章执行摘要

第3章美国分子诊断市场变数、趋势与范围

  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 普及和成长预测图
  • 产业价值链分析
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 美国分子诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 主要交易及策略联盟分析
    • 打入市场策略

第4章美国分子诊断市场：依疾病分类的预估及趋势分析

  • 2018年至2030年市场规模、预测与趋势分析

第5章美国分子诊断市场：最终用途的估计与趋势分析

  • 2018年至2030年市场规模、预测与趋势分析

第6章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争分类
  • 供应商形势
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2022 年主要市场占有率分析
    • Abbott
    • Siemens Healthcare GmbH
    • QIAGEN
    • F. Hoffmann-La Roche Ltd
    • Quest Diagnostics Incorporated
    • Danaher
    • Thermo Fisher Scientific, Inc.
    • Hologic Inc.
    • BD
    • Charles River Laboratories
    • Bio-Rad Laboratories, Inc.
    • Illumina, Inc.
    • Agilent Technologies, Inc.
Product Code: GVR-4-68040-126-4

U.S. Molecular Diagnostics Market Growth & Trends:

The U.S. molecular diagnostics market size is expected to reach USD 8.46 billion by 2030, registering a CAGR of 4.82% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market growth is attributed to increasing awareness of the benefits of adopting molecular diagnostics tests, such as early and rapid detection of viruses and bacteria. Moreover, the ease of access owing to a well-established healthcare sector coupled with favorable reimbursement policies is anticipated to drive the market growth over the forecast period.

Moreover, prominent players in the industry are investing in the technological advancement of molecular diagnostics techniques to develop solutions capable of reducing human effort and delivering instant results. For instance, QIAGEN launched the EZ2 Connect MDx platform for its application in diagnostic laboratories. The platform is equipped with a high degree of automation to purify RNA & DNA from 24 samples with a turnaround time of 30 minutes.

Developments in rapid detection assays are anticipated to support the market growth. These tests have revolutionized the market by accelerating decision-making and reducing turnaround time for decentralized testing. Numerous players are developing assays and molecular diagnostic systems. Digene HC2 GC-ID DNA test for the diagnosis of Neisseria gonorrhea, & Chlamydia trachomatis by Qiagen and ResistancePlus MG FleXible for the diagnosis of Mycoplasma genitalium with macrolide-resistance identification by Danaher Corporation (Cepheid) are examples of such products.

Major players in the market such as Abbott, Siemens Healthcare GmbH, QIAGEN, F. Hoffmann-La Roche Ltd, Danaher, Thermo Fisher Scientific, Inc., Hologic Inc., and BD, are adopting various strategies to enhance their product penetration and expand their customer base. For instance, in January 2023, Thermo Fisher Scientific and AstraZeneca entered into a collaboration to develop a blood-based and solid tissue companion diagnostic test for Tagrisso.

The COVID-19 pandemic has positively impacted the industry by encouraging players to develop rapid and novel diagnostic kits capable of detecting coronavirus. This has resulted in positive revenue growth for major market players operating in the infectious disease segment. For instance, Thermo Fisher Scientific reported 150% revenue growth owing to the rising demand for diagnostics offerings in April 2021. However, the rising adoption of vaccination in the region is anticipated to reduce the demand for COVID-19 testing over the forecast period.

U.S. Molecular Diagnostics Market Report Highlights:

  • Based on disease, the respiratory disease segment dominated the market in 2022. The growth is attributed to the increasing prevalence of respiratory infections coupled with the increasing awareness regarding the availability of diagnostic tests for diagnosing and treating infections
  • Based on end-use, the hospital core laboratory held the largest share in 2022 and is anticipated to grow at the fastest CAGR over the forecast period owing to the increasing prevalence of infections, such as MRSA, Staphylococcus aureus (SA), and enterovirus
  • Major industry players adopt different strategies such as new product launches, collaborations, acquisitions, and expansions to enhance their product penetration and gain a larger consumer base

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Disease
    • 1.1.2. End-use
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. End-use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Molecular Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Industry Value Chain Analysis
  • 3.4. Market Dynamics
    • 3.4.1. Market Driver Analysis
      • 3.4.1.1. Increase in geriatric population
      • 3.4.1.2. Introduction of technologically advanced products
      • 3.4.1.3. Increase in demand for point-of-care testing
      • 3.4.1.4. Growing prevalence of target diseases
      • 3.4.1.5. Increasing external funding for R&D
    • 3.4.2. Market Restraint Analysis
      • 3.4.2.1. Presence of Ambiguous Regulatory Framework
      • 3.4.2.2. High prices of molecular diagnostics tests
  • 3.5. U.S. Molecular Diagnostics Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic Landscape
    • 3.5.3. Major Deals & Strategic Alliances Analysis
    • 3.5.4. Market Entry Strategies

Chapter 4. U.S. Molecular Diagnostics Market: Disease Estimates & Trend Analysis

  • 4.1. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.1.1. Healthcare-Associated Infections
      • 4.1.1.1. Methicillin-Resistant Staphylococcus aureus
      • 4.1.1.1.1. Methicillin-Resistant Staphylococcus aureus Market Estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.1.2. Staphylococcus aureus
      • 4.1.1.2.1. Staphylococcus aureus Market Estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.1.3. Enterovirus
      • 4.1.1.3.1. Enterovirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.1.4. Clostridioides difficile
      • 4.1.1.4.1. Clostridioides difficile market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.1.5. Van A
      • 4.1.1.5.1. Van A market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.1.6. Sepsis Panel
      • 4.1.1.6.1. Sepsis Panel market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.2. Respiratory
      • 4.1.2.1. Flu
      • 4.1.2.1.1. Flu market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.2. Respiratory Syncytial Virus
      • 4.1.2.2.1. Respiratory Syncytial Virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.3. Paraflu
      • 4.1.2.3.1. Paraflu market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.4. Multidrug-Resistant Tuberculosis
      • 4.1.2.4.1. Multidrug-Resistant Tuberculosis market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.5. Mycobacterium Avium-Intracellular
      • 4.1.2.5.1. Mycobacterium Avium-Intracellulare market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.6. Group A Streptococcal
      • 4.1.2.6.1. Group A Streptococcal market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.7. Adenovirus
      • 4.1.2.7.1. Adenovirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.8. Human Metapneumovirus
      • 4.1.2.8.1. Human Metapneumovirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.9. Rhinoviruses
      • 4.1.2.9.1. Rhinoviruses market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.10. Middle East Respiratory Syndrome Coronavirus
      • 4.1.2.10.1. Middle East Respiratory Syndrome Coronavirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.11. Tuberculosis
      • 4.1.2.11.1. Tuberculosis market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.12. Severe Acute Respiratory Syndrome Coronavirus 2
      • 4.1.2.12.1. Severe Acute Respiratory Syndrome Coronavirus 2 market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.13. Human Bocavirus-Infection
      • 4.1.2.13.1. Human Bocavirus-Infection market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.14. Bordetella
      • 4.1.2.14.1. Bordetella market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.15. Mycoplasma Pneumonia
      • 4.1.2.15.1. Mycoplasma Pneumonia market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.2.16. Respiratory Panels
      • 4.1.2.16.1. Respiratory Panels market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.3. Gastrointestinal
      • 4.1.3.1. Norovirus
      • 4.1.3.1.1. Norovirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.2. Helicobacter pylori
      • 4.1.3.2.1. Helicobacter pylori market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.3. Shiga toxin
      • 4.1.3.3.1. Shiga toxin Market Estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.4. GI Parasite Panel
      • 4.1.3.4.1. GI Parasite Panel market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.5. GI Bacterial Panel
      • 4.1.3.5.1. GI Bacterial Panel market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.6. GI Viral Panel
      • 4.1.3.6.1. GI Viral Panel market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.3.7. GI Panels
      • 4.1.3.7.1. GI Panels market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.4. Women's Health/STI
      • 4.1.4.1. Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG)
      • 4.1.4.1.1. Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG) market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.2. Trichomonas Vaginalis
      • 4.1.4.2.1. Trichomonas Vaginalis market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.3. Mycoplasma Genitalium
      • 4.1.4.3.1. Mycoplasma genitalium market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.4. Human Papillomavirus
      • 4.1.4.4.1. Human Papillomavirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.5. Bacterial Vaginosis
      • 4.1.4.5.1. Bacterial Vaginosis market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.6. Gonorrhoea Colloquially
      • 4.1.4.6.1. Gonorrhoea Colloquially market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.7. Mycoplasma Genitalium Resistance
      • 4.1.4.7.1. Mycoplasma Genitalium Resistance market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.8. Herpes Simplex Virus
      • 4.1.4.8.1. Herpes Simplex Virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.4.9. Group B Streptococcus
      • 4.1.4.9.1. Group B Streptococcus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.5. Immunocompromised
      • 4.1.5.1. Cytomegalovirus
      • 4.1.5.1.1. Cytomegalovirus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.5.2. Epstein-Barr virus
      • 4.1.5.2.1. Epstein-Barr virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.5.3. Varicella-Zoster Virus
      • 4.1.5.3.1. Varicella-Zoster Virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.5.4. BK virus
      • 4.1.5.4.1. BK virus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.6. Virology
      • 4.1.6.1. Human immunodeficiency viruses
      • 4.1.6.1.1. Human immunodeficiency viruses market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.6.2. Hepatitis C virus
      • 4.1.6.2.1. Hepatitis C virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.6.3. Hepatitis B virus
      • 4.1.6.3.1. Hepatitis B virus Market Estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.6.4. Hepatitis E virus
      • 4.1.6.4.1. Hepatitis E virus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.7. Other Targets
      • 4.1.7.1. Babesia
      • 4.1.7.1.1. Babesia market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.2. Zika
      • 4.1.7.2.1. Zika market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.3. West Nile Virus
      • 4.1.7.3.1. West Nile Virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.4. Chikungunya virus/Dengue virus
      • 4.1.7.4.1. Chikungunya virus/Dengue Virus Market Estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.5. Enhancer of zeste homolog 2
      • 4.1.7.5.1. Enhancer of zeste homolog 2 market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.6. PIK3CA
      • 4.1.7.6.1. PIK3CA market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.7. Malaria
      • 4.1.7.7.1. Malaria market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.7.8. Monkeypox Virus
      • 4.1.7.8.1. Monkeypox Virus market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.8. Other Panels
      • 4.1.8.1. Meningitis Panel
      • 4.1.8.1.1. Meningitis Panel market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.8.2. Lyme Panel
      • 4.1.8.2.1. Lyme Panel market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.8.3. UTI Panel
      • 4.1.8.3.1. UTI Panel market estimates and forecast 2018 to 2030 (USD Million)
    • 4.1.9. Oncology
      • 4.1.9.1. Microsatellite Instability
      • 4.1.9.1.1. Microsatellite Instability market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.9.2. B-raf
      • 4.1.9.2.1. B-raf market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.9.3. Epidermal Growth Factor Receptor
      • 4.1.9.3.1. Epidermal Growth Factor Receptor market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.9.4. Kirsten Rat Sarcoma Virus
      • 4.1.9.4.1. Kirsten Rat Sarcoma Virus market estimates and forecast 2018 to 2030 (USD Million)
      • 4.1.9.5. Others
      • 4.1.9.5.1. Others Market Estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. U.S. Molecular Diagnostics Market: End-use Estimates & Trend Analysis

  • 5.1. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.1.1. Hospital Core Laboratory
      • 5.1.1.1. Hospital Core Laboratory market estimates and forecast 2018 to 2030 (USD Million)
    • 5.1.2. Hospital Alternative Sites
      • 5.1.2.1. Hospital Alternative Sites market estimates and forecast 2018 to 2030 (USD Million)
    • 5.1.3. Decentralized Test Sites
      • 5.1.3.1. Decentralized Test Site market estimates and forecast 2018 to 2030 (USD Million)
    • 5.1.4. Reference Lab
      • 5.1.4.1. Reference Lab market Estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. List of key distributors and channel partners
    • 6.3.2. Key customers
    • 6.3.3. Key Company Market Share Analysis, 2022
    • 6.3.4. Abbott
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives
    • 6.3.5. Siemens Healthcare GmbH
      • 6.3.5.1. Company overview
      • 6.3.5.2. Financial performance
      • 6.3.5.3. Product benchmarking
      • 6.3.5.4. Strategic initiatives
    • 6.3.6. QIAGEN
      • 6.3.6.1. Company overview
      • 6.3.6.2. Financial performance
      • 6.3.6.3. Product benchmarking
      • 6.3.6.4. Strategic initiatives
    • 6.3.7. F. Hoffmann-La Roche Ltd
      • 6.3.7.1. Company overview
      • 6.3.7.2. Financial performance
      • 6.3.7.3. Product benchmarking
      • 6.3.7.4. Strategic initiatives
    • 6.3.8. Quest Diagnostics Incorporated
      • 6.3.8.1. Company overview
      • 6.3.8.2. Financial performance
      • 6.3.8.3. Product benchmarking
      • 6.3.8.4. Strategic initiatives
    • 6.3.9. Danaher
      • 6.3.9.1. Company overview
      • 6.3.9.2. Financial performance
      • 6.3.9.3. Product benchmarking
      • 6.3.9.4. Strategic initiatives
    • 6.3.10. Thermo Fisher Scientific, Inc.
      • 6.3.10.1. Company overview
      • 6.3.10.2. Financial performance
      • 6.3.10.3. Product benchmarking
      • 6.3.10.4. Strategic initiatives
    • 6.3.11. Hologic Inc.
      • 6.3.11.1. Company overview
      • 6.3.11.2. Financial performance
      • 6.3.11.3. Product benchmarking
      • 6.3.11.4. Strategic initiatives
    • 6.3.12. BD
      • 6.3.12.1. Company overview
      • 6.3.12.2. Financial performance
      • 6.3.12.3. Product benchmarking
      • 6.3.12.4. Strategic initiatives
    • 6.3.13. Charles River Laboratories
      • 6.3.13.1. Company overview
      • 6.3.13.2. Financial performance
      • 6.3.13.3. Product benchmarking
      • 6.3.13.4. Strategic initiatives
    • 6.3.14. Bio-Rad Laboratories, Inc.
      • 6.3.14.1. Company overview
      • 6.3.14.2. Financial performance
      • 6.3.14.3. Product benchmarking
      • 6.3.14.4. Strategic initiatives
    • 6.3.15. Illumina, Inc.
      • 6.3.15.1. Company Overview
      • 6.3.15.2. Financial performance
      • 6.3.15.3. Product benchmarking
      • 6.3.15.4. Strategic initiatives
    • 6.3.16. Agilent Technologies, Inc.
      • 6.3.16.1. Company Overview
      • 6.3.16.2. Financial performance
      • 6.3.16.3. Product benchmarking
      • 6.3.16.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 List of Secondary Sources
  • Table 3 U.S. Molecular Diagnostics Market, by Disease, 2018 - 2030 (USD Million)
  • Table 4 U.S. Molecular Diagnostics Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. molecular diagnostics market: market outlook
  • Fig. 9 U.S. Molecular Diagnostics Market Competitive Insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 U.S. molecular diagnostics market driver impact
  • Fig. 15 U.S. molecular diagnostics market restraint impact
  • Fig. 16 U.S. Molecular Diagnostics Market Strategic Initiatives Analysis
  • Fig. 17 U.S. molecular diagnostics market: disease movement analysis
  • Fig. 18 U.S. molecular diagnostics market: disease outlook and key takeaways
  • Fig. 19 Methicillin-Resistant Staphylococcus aureus market estimates and forecast, 2018 - 2030
  • Fig. 20 Staphylococcus aureus market estimates and forecast, 2018 - 2030
  • Fig. 21 Enterovirus market estimates and forecast, 2018 - 2030
  • Fig. 22 Clostridioides difficile market estimates and forecast, 2018 - 2030
  • Fig. 23 Van A market estimates and forecast, 2018 - 2030
  • Fig. 24 Sepsis Panel market estimates and forecast, 2018 - 2030
  • Fig. 25 Flu market estimates and forecast, 2018 - 2030
  • Fig. 26 Respiratory Syncytial Virus market estimates and forecast, 2018 - 2030
  • Fig. 27 Paraflu market estimates and forecast, 2018 - 2030
  • Fig. 28 Multidrug-Resistant Tuberculosis market estimates and forecast, 2018 - 2030
  • Fig. 29 Mycobacterium Avium-Intracellulare market estimates and forecast, 2018 - 2030
  • Fig. 30 Group A Streptococcal market estimates and forecast, 2018 - 2030
  • Fig. 31 Adenovirus market estimates and forecast, 2018 - 2030
  • Fig. 32 Human Metapneumovirus market estimates and forecast, 2018 - 2030
  • Fig. 33 Rhinoviruses market estimates and forecast, 2018 - 2030
  • Fig. 34 Middle East Respiratory Syndrome Coronavirus market estimates and forecast, 2018 - 2030
  • Fig. 35 Tuberculosis market estimates and forecast, 2018 - 2030
  • Fig. 36 Severe Acute Respiratory Syndrome Coronavirus 2 market estimates and forecast, 2018 - 2030
  • Fig. 37 Human Bocavirus-Infection market estimates and forecast, 2018 - 2030
  • Fig. 38 Bordetella market estimates and forecast, 2018 - 2030
  • Fig. 39 Mycoplasma Pneumonia market estimates and forecast, 2018 - 2030
  • Fig. 40 Respiratory Panels market estimates and forecast, 2018 - 2030
  • Fig. 41 Norovirus market estimates and forecast, 2018 - 2030
  • Fig. 42 Helicobacter pylori market estimates and forecast, 2018 - 2030
  • Fig. 43 Shiga toxin market estimates and forecast, 2018 - 2030
  • Fig. 44 GI Parasite Panel market estimates and forecast, 2018 - 2030
  • Fig. 45 GI Bacterial Panel market estimates and forecast, 2018 - 2030
  • Fig. 46 GI Viral Panel market estimates and forecast, 2018 - 2030
  • Fig. 47 GI Panels market estimates and forecast, 2018 - 2030
  • Fig. 48 Women's Health/STI market estimates and forecast, 2018 - 2030
  • Fig. 49 Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG) market estimates and forecast, 2018 - 2030
  • Fig. 50 Trichomonas Vaginalis market estimates and forecast, 2018 - 2030
  • Fig. 51 Mycoplasma Genitalium market estimates and forecast, 2018 - 2030
  • Fig. 52 Human Papillomavirus market estimates and forecast, 2018 - 2030
  • Fig. 53 Bacterial Vaginosis market estimates and forecast, 2018 - 2030
  • Fig. 54 Gonorrhoea Colloquially market estimates and forecast, 2018 - 2030
  • Fig. 55 Mycoplasma Genitalium Resistance market estimates and forecast, 2018 - 2030
  • Fig. 56 Herpes Simplex Virus market estimates and forecast, 2018 - 2030
  • Fig. 57 Group B Streptococcus market estimates and forecast, 2018 - 2030
  • Fig. 58 Cytomegalovirus market estimates and forecast, 2018 - 2030
  • Fig. 59 Epstein-Barr virus market estimates and forecast, 2018 - 2030
  • Fig. 60 Varicella-Zoster Virus market estimates and forecast, 2018 - 2030
  • Fig. 61 BK virus market estimates and forecast, 2018 - 2030
  • Fig. 62 Human immunodeficiency viruses market estimates and forecast, 2018 - 2030
  • Fig. 63 Hepatitis C virus market estimates and forecast, 2018 - 2030
  • Fig. 64 Hepatitis B virus market estimates and forecast, 2018 - 2030
  • Fig. 65 Hepatitis E virus market estimates and forecast, 2018 - 2030
  • Fig. 66 Babesia market estimates and forecast, 2018 - 2030
  • Fig. 67 Zika market estimates and Forecast, 2018 - 2030
  • Fig. 68 West Nile Virus market estimates and forecast, 2018 - 2030
  • Fig. 69 Chikungunya virus/dengue virus market estimates and forecast, 2018 - 2030
  • Fig. 70 Enhancer of zest homolog 2 market estimates and forecast, 2018 - 2030
  • Fig. 71 PIK3CA market estimates and forecast, 2018 - 2030
  • Fig. 72 Malaria market estimates and forecast, 2018 - 2030
  • Fig. 73 Monkeypox Virus market estimates and forecast, 2018 - 2030
  • Fig. 74 Meningitis Panel market estimates and forecast, 2018 - 2030
  • Fig. 75 Lyme Panel market estimates and forecast, 2018 - 2030
  • Fig. 76 UTI Panel market estimates and forecast, 2018 - 2030
  • Fig. 77 Microsatellite Instability market estimates and forecast, 2018 - 2030
  • Fig. 78 B-raf market estimates and forecast, 2018 - 2030
  • Fig. 79 Epidermal Growth Factor Receptor market estimates and forecast, 2018 - 2030
  • Fig. 80 Kirsten rat sarcoma virus market estimates and forecast, 2018 - 2030
  • Fig. 81 Other market estimates and forecast, 2018 - 2030
  • Fig. 82 U.S. molecular diagnostics market: end-use movement analysis
  • Fig. 83 U.S. molecular diagnostics market: end-use outlook and key takeaways
  • Fig. 84 Hospital Core Laboratory market estimates and forecast, 2018 - 2030
  • Fig. 85 Hospital Alternative Sites market estimates and forecast, 2018 - 2030
  • Fig. 86 Decentralized Test Sites market estimates and forecast, 2018 - 2030
  • Fig. 87 Reference Lab market estimates and forecast, 2018 - 2030
  • Fig. 88 Participant categorization- U.S. molecular diagnostics market
  • Fig. 89 Market share of key market players- U.S. molecular diagnostics market